1-2 of 2
Wei-Shu Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

Ming Yin, Jingrong Yan, Eva Martinez-Balibrea, Francesco Graziano, Heinz-Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock-Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1632–1640.
https://doi.org/10.1158/1078-0432.CCR-10-2169
Published: 15 March 2011
View article titled, <em>ERCC1</em> and <em>ERCC2</em> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
Open the PDF for <em>ERCC1</em> and <em>ERCC2</em> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis in another window
Journal Articles

Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma

Wei-Shu Wang, Po-Min Chen, Tzeon-Jye Chiou, Jin-Hwang Liu, Jen-Kou Lin, Tzu-Chen Lin, Huann-Sheng Wang, Yeu Su
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3597–3604.
https://doi.org/10.1158/1078-0432.CCR-06-2601
Published: 15 June 2007
View article titled, Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma
Open the PDF for Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma in another window